Expression of p16, Rb and FHIT proteins in urothelial carcinoma of the urinary bladder

Korean Journal of Pathology

Volumn 42, Issue 5, 2008, Pages 294-298

  Han, Sun Hee ^a   Lee, Ju Han ^a   Kim, Seo Hee ^a   An, Jungsuk ^a   Lee, Eung Seok ^a   Kim, Young Sik ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Bladder cancer; FHIT protein; P16INK4A protein; Retinoblastoma protein

Indexed keywords

EID: 59849089417     PISSN: 17381843     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Mhawech-Fauceglia P, Cheney RT, Schwaller J. Genetic alterations in urothelial bladder carcinoma: an updated review. Cancer 2006; 106: 1205-16.
2. Borden LS Jr, Clark PE, Hall MC. Bladder cancer. Curr Opin Oncol 2003; 15: 227-33.
3. Rocco JW, Sidransky D. p16(MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res 2001; 264: 42-55.
4. Williamson MP, Elder PA, Shaw ME, Devlin J, Knowles MA. p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer. Hum Mol Genet 1995; 4: 1569-77.
5. Yeager TR, DeVries S, Jarrard DF, et al. Overcoming cellular senescence in human cancer pathogenesis. Genes Dev 1998; 12: 163-74.
6. Krüger S, Mahnken A, Kausch I, Feller AC. P16 immunoreactivity is an independent predictor of tumor progression in minimally invasive urothelial bladder carcinoma. Eur Urol 2005; 47: 463-7.
7. Hitchings AW, Kumar M, Jordan S, Nargund V, Martin J, Berney DM. Prediction of progression in pTa and pT1 bladder carcinomas with p53, p16 and pRb. Br J Cancer 2004; 91: 552-7.
8. Shariat SF, Tokunaga H, Zhou J, et al. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol 2004; 22: 1014-24.
9. Le Frère-Belda MA, Gil Diez de Medina S, Daher A, et al. Profiles of the 2 INK4a gene products, p16 and p14ARF, in human reference urothelium and bladder carcinomas, according to pRb and p53 protein status. Hum Pathol 2004; 35: 817-24.
10. ink4 immunoreactivity is a reliable marker for urothelial carcinoma in situ. Hum Pathol 2008; 39: 527-35.
11. Klaes R, Friedrich T, Spitkovsky D, et al. Overexpression of p16 (INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001; 92: 276-84.
12. Chatterjee SJ, Datar R, Youssefzadeh D, et al. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol 2004; 22: 1007-13.
13. Grossman HB, Liebert M, Antelo M, et al. p53 and RB expression predict progression in T1 bladder cancer. Clin Cancer Res 1998; 4: 829-34.
14. Cordon-Cardo C, Zhang ZF, Dalbagni G, et al. Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res 1997; 57: 1217-21.
15. Santos LL, Amaro T, Pereira SA, et al. Expression of cell-cycle regulatory proteins and their prognostic value in superficial low-grade urothelial cell carcinoma of the bladder. Eur J Surg Oncol 2003; 29: 74-80.
16. Vecchione A, Sevignani C, Giarnieri E, et al. Inactivation of the FHIT gene favors bladder cancer development. Clin Cancer Res 2004; 10: 7607-12.
17. Skopelitou AS, Gloustianou G, Bai M, Huebner K. FHIT gene expression in human urinary bladder transitional cell carcinomas. In Vivo 2001; 15: 169-73.